MCP
TXG icon

Mirador Capital Partners’s 10x Genomics TXG Stock Holding History

Mirador Capital Partners’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.44M Sell
63,636
-13,657
-18% -$358K 0.3% 61
2026
Q1 		$1.64M Buy
77,293
+960
+1% +$19.2K 0.23% 67
2025
Q4 		$1.24M Sell
76,333
-4,849
-6% -$73.3K 0.17% 87
2025
Q3 		$949K Buy
81,182
+1,739
+2% +$22.7K 0.13% 108
2025
Q2 		$920K Sell
79,443
-814
-1% -$7.42K 0.15% 98
2025
Q1 		$701K Sell
80,257
-726
-0.9% -$9.15K 0.12% 112
2024
Q4 		$1.16M Buy
80,983
+22,792
+39% +$360K 0.21% 79
2024
Q3 		$1.31M Sell
58,191
-3,776
-6% -$78.1K 0.24% 67
2024
Q2 		$1.21M Buy
61,967
+33,142
+115% +$868K 0.23% 68
2024
Q1 		$1.08M Buy
28,825
+940
+3% +$41.3K 0.21% 80
2023
Q4 		$1.56M Buy
27,885
+521
+2% +$22.7K 0.33% 59
2023
Q3 		$1.13M Sell
27,364
-4,480
-14% -$233K 0.26% 72
2023
Q2 		$1.78M Sell
31,844
-1,205
-4% -$65.2K 0.42% 59
2023
Q1 		$1.84M Buy
33,049
+6,478
+24% +$303K 0.44% 54
2022
Q4 		$968K Sell
26,571
-1,710
-6% -$55.9K 0.23% 73
2022
Q3 		$805K Buy
28,281
+12,587
+80% +$480K 0.19% 79
2022
Q2 		$710K Sell
15,694
-6,253
-28% -$324K 0.17% 94
2022
Q1 		$1.67M Buy
21,947
+464
+2% +$40.6K 0.34% 64
2021
Q4 		$3.2M Buy
21,483
+1,353
+7% +$207K 0.67% 46
2021
Q3 		$2.93M Buy
20,130
+4,519
+29% +$776K 0.67% 45
2021
Q2 		$3.06M Buy
15,611
+1,425
+10% +$258K 0.69% 49
2021
Q1 		$2.57M Sell
14,186
-191
-1% -$33K 0.66% 48
2020
Q4 		$2.04M Buy
14,377
+938
+7% +$136K 0.56% 59
2020
Q3 		$1.68M Buy
13,439
+588
+5% +$61.7K 0.52% 56
2020
Q2 		$1.15M Buy
12,851
+557
+5% +$43.4K 0.43% 58
2020
Q1 		$968K Buy
12,294
+7,994
+186% +$624K 0.4% 60
2019
Q4 		$328K Buy
+4,300
New +$259K 0.13% 134

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Mirador Capital Partners's TXG Position: Q2 2026 in Review

Mirador Capital Partners reduced its 10x Genomics (TXG) stake by 18% in Q2 2026, selling an estimated $358K and leaving 63,636 shares worth $2.44M. The position accounts for 0.3% of the portfolio, ranked #61.

Mirador Capital Partners first reported a position in TXG in Q4 2019 and has held it in 27 quarters since. The position peaked at $3.2M in Q4 2021. 390 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

  • Mirador Capital Partners held 63,636 shares of 10x Genomics worth $2.44M as of Q2 2026.
  • Mirador Capital Partners sold 13,657 10x Genomics shares in Q2 2026, an estimated $358K.
  • 10x Genomics made up 0.3% of Mirador Capital Partners's portfolio in Q2 2026, its #61 holding.
  • Mirador Capital Partners first reported a position in 10x Genomics in Q4 2019 and has held it in 27 quarters since.
  • Mirador Capital Partners's 10x Genomics position peaked at $3.2M in Q4 2021.
  • 390 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on Mirador Capital Partners's 13F filing for Q2 2026, filed 7 Jul 2026.